
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6618867/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	ESTIMATION OF THE COANCESTRY COEFFICIENT: BASIS FOR A SHORT-TERM GENETIC DISTANCE. Genetics, 1983, 105, 767-779.	1.2	1,545
2	Estimation of soil microbial c by a fumigation-extraction method: use on soils of high organic matter content, and a reassessment of the kec-factor. Soil Biology and Biochemistry, 1990, 22, 301-307.	4.2	366
3	International Randomized Study of Interferon Vs STI571 (IRIS) 8-Year Follow up: Sustained Survival and Low Risk for Progression or Events in Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Treated with Imatinib Blood, 2009, 114, 1126-1126.	0.6	358
4	Consolidation Therapy With Low-Dose Thalidomide and Prednisolone Prolongs the Survival of Multiple Myeloma Patients Undergoing a Single Autologous Stem-Cell Transplantation Procedure. Journal of Clinical Oncology, 2009, 27, 1788-1793.	0.8	315
5	All-trans-retinoic acid, idarubicin, and IV arsenic trioxide as initial therapy in acute promyelocytic leukemia (APML4). Blood, 2012, 120, 1570-1580.	0.6	268
6	Ibrutinib inhibits collagen-mediated but not ADP-mediated platelet aggregation. Leukemia, 2015, 29, 783-787.	3.3	191
7	Freezing and thawing rate effects on drip loss from samples of pork. Meat Science, 1999, 53, 149-158.	2.7	166
8	Impact of early dose intensity on cytogenetic and molecular responses in chronic- phase CML patients receiving 600 mg/day of imatinib as initial therapy. Blood, 2008, 112, 3965-3973.	0.6	160
9	Early molecular response and female sex strongly predict stable undetectable BCR-ABL1, the criteria for imatinib discontinuation in patients with CML. Blood, 2013, 121, 3818-3824.	0.6	153
10	Use of arsenic trioxide in remission induction and consolidation therapy for acute promyelocytic leukaemia in the Australasian Leukaemia and Lymphoma Group (ALLG) APML4 study: a non-randomised phase 2 trial. Lancet Haematology,the, 2015, 2, e357-e366.	2.2	133
11	Chemotherapy and Venetoclax in Elderly Acute Myeloid Leukemia Trial (CAVEAT): A Phase Ib Dose-Escalation Study of Venetoclax Combined With Modified Intensive Chemotherapy. Journal of Clinical Oncology, 2020, 38, 3506-3517.	0.8	112
12	The Effects of Exercise Training in Addition to Energy Restriction on Functional Capacities and Body Composition in Obese Adults during Weight Loss: A Systematic Review. PLoS ONE, 2013, 8, e81692.	1.1	109
13	Mothers after Gestational Diabetes in Australia (MAGDA): A Randomised Controlled Trial of a Postnatal Diabetes Prevention Program. PLoS Medicine, 2016, 13, e1002092.	3.9	89
14	Anti-CD8 Monoclonal Antibody Therapy Is Effective in the Prevention and Treatment of Experimental Autoimmune Glomerulonephritis. Journal of the American Society of Nephrology: JASN, 2002, 13, 359-369.	3.0	81
15	Unmet needs and depression among carers of people newly diagnosed with cancer. European Journal of Cancer, 2015, 51, 2049-2057.	1.3	75
16	ldentification of MicroRNAs Linked to Regulators of Muscle Protein Synthesis and Regeneration in Young and Old Skeletal Muscle. PLoS ONE, 2014, 9, e114009.	1.1	74
17	Pamidronate Reduces Bone Loss after Allogeneic Stem Cell Transplantation. Journal of Clinical Endocrinology and Metabolism, 2006, 91, 3835-3843.	1.8	70
18	Effect of Cognitive Bias Modification on Early Relapse Among Adults Undergoing Inpatient Alcohol Withdrawal Treatment. JAMA Psychiatry, 2021, 78, 133.	6.0	65

#	Article	IF	CITATIONS
19	Microbial activity and survival in soils dried at different rates. Soil Research, 1992, 30, 209.	0.6	64
20	Freezing rate and frozen storage effects on the ultrastructure of samples of pork. Meat Science, 1999, 53, 159-168.	2.7	60
21	Jamie's Ministry of Food: Quasi-Experimental Evaluation of Immediate and Sustained Impacts of a Cooking Skills Program in Australia. PLoS ONE, 2014, 9, e114673.	1.1	60
22	Reproducibility of "Intelligent―Contouring of Gross Tumor Volume in Non–Small-Cell Lung Cancer on PET/CT Images Using a Standardized Visual Method. International Journal of Radiation Oncology Biology Physics, 2010, 77, 1151-1157.	0.4	59
23	Results of the APML3 trial incorporating all-trans-retinoic acid and idarubicin in both induction and consolidation as initial therapy for patients with acute promyelocytic leukemia. Haematologica, 2012, 97, 227-234.	1.7	57
24	The Acceptability Among Health Researchers and Clinicians of Social Media to Translate Research Evidence to Clinical Practice: Mixed-Methods Survey and Interview Study. Journal of Medical Internet Research, 2015, 17, e119.	2.1	57
25	Formation of cortical plasticity in older adults following tDCS and motor training. Frontiers in Aging Neuroscience, 2013, 5, 87.	1.7	54
26	Infliximab and adalimumab drug levels in Crohn's disease: contrasting associations with disease activity and influencing factors. Alimentary Pharmacology and Therapeutics, 2017, 46, 150-161.	1.9	53
27	Wider impacts of a 10-week community cooking skills program - Jamie's Ministry of Food, Australia. BMC Public Health, 2014, 14, 1161.	1.2	49
28	Monitoring tumour burden and therapeutic response through analysis of circulating tumour DNA and extracellular RNA in multiple myeloma patients. Leukemia, 2019, 33, 2022-2033.	3.3	49
29	Red cell alloimmunization is associated with development of autoantibodies and increased red cell transfusion requirements in myelodysplastic syndrome. Haematologica, 2017, 102, 2021-2029.	1.7	45
30	Translating Evidence Into Practice via Social Media: A Mixed-Methods Study. Journal of Medical Internet Research, 2015, 17, e242.	2.1	45
31	Risk-reducing surgery in women with familial susceptibility for breast and/or ovarian cancer. European Journal of Cancer, 2006, 42, 621-628.	1.3	43
32	Satisfaction with the decision to participate in cancer clinical trials is high, but understanding is a problem. Supportive Care in Cancer, 2011, 19, 371-379.	1.0	41
33	A pragmatic randomized controlled trial exploring the relationship between pulse number and response to repetitive transcranial magnetic stimulation treatment in depression. Brain Stimulation, 2020, 13, 145-152.	0.7	41
34	The collection of oocytes from bovine ovaries. Theriogenology, 1997, 47, 977-987.	0.9	40
35	Intraâ€patient variability in adalimumab drug levels within and between cycles in Crohn's disease. Alimentary Pharmacology and Therapeutics, 2017, 45, 1135-1145.	1.9	40
36	Efficacy of a telephone outcall program to reduce caregiver burden among caregivers of cancer patients [PROTECT]: a randomised controlled trial. BMC Cancer, 2018, 18, 59.	1.1	39

JOHN REYNOLDS

#	Article	IF	CITATIONS
37	Screening behavior in women at increased familial risk for breast cancer. Familial Cancer, 2006, 5, 359-368.	0.9	38
38	Randomised clinical trial: efficacy, safety and dosage of adjunctive allopurinol in azathioprine/mercaptopurine nonresponders (<scp>AAA</scp> Study). Alimentary Pharmacology and Therapeutics, 2018, 47, 1092-1102.	1.9	38
39	TGF-α and IL-6 plasma levels selectively identify CML patients who fail to achieve an early molecular response or progress in the first year of therapy. Leukemia, 2016, 30, 1263-1272.	3.3	37
40	Pre-operative sera interleukin-6 in the diagnosis of high-grade serous ovarian cancer. Scientific Reports, 2020, 10, 2213.	1.6	37
41	The evolution of crescentic nephritis and alveolar haemorrhage following induction of autoimmunity to glomerular basement membrane in an experimental model of Goodpasture's disease. Journal of Pathology, 2003, 200, 118-129.	2.1	32
42	Relationships between inflammatory cytokine and cortisol responses in firefighters exposed to simulated wildfire suppression work and sleep restriction. Physiological Reports, 2015, 3, e12604.	0.7	31
43	Sex-Differential Non-Vaccine-Specific Immunological Effects of Diphtheria-Tetanus-Pertussis and Measles Vaccination. Clinical Infectious Diseases, 2016, 63, ciw492.	2.9	31
44	Playing Active Video Games may not develop movement skills: An intervention trial. Preventive Medicine Reports, 2015, 2, 673-678.	0.8	28
45	Methyl-Green-Pyronin as a Differential Nucleic Acid Stain for Peripheral Blood Smears. Blood, 1956, 11, 1132-1139.	0.6	27
46	Gene expression signature that predicts early molecular response failure in chronic-phase CML patients on frontline imatinib. Blood Advances, 2019, 3, 1610-1621.	2.5	27
47	The effects of linkage and linkage disequilibrium on the covariances of noninbred relatives. Heredity, 1980, 45, 351-359.	1.2	26
48	A prospective comparison of cold snare polypectomy using traditional or dedicated cold snares for the resection of small sessile colorectal polyps. Endoscopy International Open, 2017, 05, E1062-E1068.	0.9	26
49	Dynamic assessment of RBCâ€transfusion dependency improves the prognostic value of the revisedâ€ŀPSS in MDS patients. American Journal of Hematology, 2017, 92, 508-514.	2.0	25
50	A Prospective Multicenter Trial of Peripheral Blood Stem Cell Sibling Allografts for Acute Myeloid Leukemia in First Complete Remission Using Fludarabine-Cyclophosphamide Reduced Intensity Conditioning. Biology of Blood and Marrow Transplantation, 2007, 13, 560-567.	2.0	24
51	Translating evidence to practice in the health professions: a randomized trial of Twitter vs Facebook. Journal of the American Medical Informatics Association: JAMIA, 2017, 24, 403-408.	2.2	24
52	A preliminary investigation of the effects of frozen storage on samples of pork. Meat Science, 1999, 53, 169-177.	2.7	23
53	Influence of duration of supplementation with ruminally protected linseed oil on the fatty acid composition of feedlot lambs. Animal Feed Science and Technology, 2009, 151, 228-239.	1.1	23
54	Prediction of outcomes in patients with Ph+ chronic myeloid leukemia in chronic phase treated with nilotinib after imatinib resistance/intolerance. Leukemia, 2013, 27, 907-913.	3.3	23

#	Article	IF	CITATIONS
55	The impact of sleep restriction while performing simulated physical firefighting work on cortisol and heart rate responses. International Archives of Occupational and Environmental Health, 2016, 89, 461-475.	1.1	23
56	Patient activation intervention to facilitate participation in recovery after total knee replacement (MIME): a cluster randomised cross-over trial. BMJ Quality and Safety, 2019, 28, 782-792.	1.8	23
57	Influence of soil moisture regime on the respiration response of soils subjected to osmotic stress. Soil Research, 1989, 27, 161.	0.6	23
58	Microbiota of little penguins and short-tailed shearwaters during development. PLoS ONE, 2017, 12, e0183117.	1.1	23
59	Challenges of diabetes prevention in the real world: results and lessons from the Melbourne Diabetes Prevention Study. BMJ Open Diabetes Research and Care, 2015, 3, e000131.	1.2	22
60	<i>Helicobacter pylori</i> CagL Hypervariable Motif: A Global Analysis of Geographical Diversity and Association With Gastric Cancer. Journal of Infectious Diseases, 2016, 213, 1927-1931.	1.9	21
61	The variance of sample heterozygosity. Theoretical Population Biology, 1990, 37, 235-253.	0.5	20
62	Comprehension of pesticide safety information: Effects of pictorial and textual warnings. International Journal of Pest Management, 1997, 43, 239-245.	0.9	20
63	Folic Acid Supplementation in Postpolypectomy Patients in a Randomized Controlled Trial Increases Tissue Folate Concentrations and Reduces Aberrant DNA Biomarkers in Colonic Tissues Adjacent to the Former Polyp Site. Journal of Nutrition, 2016, 146, 933-939.	1.3	20
64	The Effect of Chloramphenicol and Other Antibiotics on Leukocyte Respiration. Blood, 1956, 11, 234-242.	0.6	17
65	Psychophysiological relationships between a multi-component self-report measure of mood, stress and behavioural signs and symptoms, and physiological stress responses during a simulated firefighting deployment. International Journal of Psychophysiology, 2016, 110, 109-118.	0.5	17
66	ASXL1 and BIM germ line variants predict response and identify CML patients with the greatest risk of imatinib failure. Blood Advances, 2017, 1, 1369-1381.	2.5	17
67	Influence of pH, exchangeable aluminium and 0.02M CaCl2-extractable aluminium on the growth and nitrogen-fixing activity of white clover (Trifolium repens) in some New Zealand soils. Plant and Soil, 1988, 111, 111-119.	1.8	16
68	Acute Psychophysiological Relationships Between Mood, Inflammatory and Cortisol Changes in Response to Simulated Physical Firefighting Work and Sleep Restriction. Applied Psychophysiology Biofeedback, 2016, 41, 165-180.	1.0	16
69	DNA-Repair Gene Mutations Are Highly Prevalent in Circulating Tumour DNA from Multiple Myeloma Patients. Cancers, 2019, 11, 917.	1.7	16
70	The Effect of Overweight/Obesity on Cardiovascular Responses to Acute Psychological Stress in Men Aged 50-70 Years. Obesity Facts, 2014, 7, 339-350.	1.6	15
71	Rater agreement of a test battery designed to assess adolescents' resistance training skill competency. Journal of Science and Medicine in Sport, 2015, 18, 72-76.	0.6	14
72	Molecular Patterns of Response and Outcome in the Chemotherapy and Venetoclax in Elderly AML Trial (CAVEAT study). Blood, 2018, 132, 333-333.	0.6	14

#	Article	IF	CITATIONS
73	Alcohol use in the year following approach bias modification during inpatient withdrawal: secondary outcomes from a doubleâ€blind, multiâ€site randomized controlled trial. Addiction, 2022, 117, 2837-2846.	1.7	14
74	Restricted cell cycle is essential for clonal evolution and therapeutic resistance of pre-leukemic stem cells. Nature Communications, 2018, 9, 3535.	5.8	13
75	Oral azacitidine (CC-486) in combination with lenalidomide and dexamethasone in advanced, lenalidomide-refractory multiple myeloma (ROAR study). Leukemia and Lymphoma, 2019, 60, 2143-2151.	0.6	13
76	Patient participation in postoperative care activities in patients undergoing total knee replacement surgery: Multimedia Intervention for Managing patient Experience (MIME). Study protocol for a cluster randomised crossover trial. BMC Musculoskeletal Disorders, 2016, 17, 294.	0.8	10
77	The Majority of Chronic Myeloid Leukaemia Patients Who Cease Imatinib after Achieving a Sustained Complete Molecular Response (CMR) Remain in CMR, and Any Relapses Occur Early Blood, 2008, 112, 1102-1102.	0.6	10
78	Luciferase preparation, assay conditions and calculated extraction efficiency as factors in the estimation of soil ATP content. Biology and Fertility of Soils, 1986, 2, 205.	2.3	9
79	Prognostic features for response and survival in elderly patients withde novoacute myeloid leukemia treated with mitoxantrone and intermediate dose cytarabine. Leukemia and Lymphoma, 2005, 46, 367-375.	0.6	9
80	Minimal Sex-Differential Modulation of Reactivity to Pathogens and Toll-Like Receptor Ligands following Infant Bacillus Calmette–Guérin Russia Vaccination. Frontiers in Immunology, 2017, 8, 1092.	2.2	9
81	Lenalidomide maintenance treatment after imatinib discontinuation: results of a phase 1 clinical trial in chronic myeloid leukaemia. British Journal of Haematology, 2019, 186, e56-e60.	1.2	9
82	Integrated clinical and genomic evaluation of guadecitabine (SGI-110) in peripheral T-cell lymphoma. Leukemia, 2022, 36, 1654-1665.	3.3	9
83	A Comparison of Human Leukocyte Phosphatase Activity toward Sodium β-Glycerophosphate, Adenosine 5'-Phosphate and Glucose 1-Phosphate. Blood, 1959, 14, 415-422.	0.6	8
84	Effects of salinity, temperature, and light intensity on the growth rates of two halophilic phytoflagellates in mixed culture. New Zealand Journal of Marine and Freshwater Research, 1986, 20, 467-478.	0.8	8
85	The extraction of Al, Fe and Si from a range of New Zealand soils by hydroxylamine and ammonium oxalate solutions. Soil Research, 1989, 27, 377.	0.6	8
86	Maintenance of Imatinib Dose Intensity in the First Six Months of Therapy for Newly Diagnosed Patients with CML Is Predictive of Molecular Response, Independent of the Ability To Increase Dose at a Later Point Blood, 2005, 106, 164-164.	0.6	8
87	Reproducibility of "Intelligent―Contouring of Gross Tumor Volume in Non-Small Cell Lung Cancer on PET/CT Images Using a Standardized Visual Method. International Journal of Radiation Oncology Biology Physics, 2007, 69, S154-S155.	0.4	7
88	Bayesian adaptive design: the future for regional anesthesia trials?. Regional Anesthesia and Pain Medicine, 2019, 44, 617-622.	1.1	7
89	Sequential Blinatumomab with Reduced Intensity Chemotherapy in the Treatment of Older Adults with Newly Diagnosed Ph Negative B-Precursor Acute Lymphoblastic Leukemia - Interim Analysis of the Australasian Leukemia and Lymphoma Group ALL08 Study. Blood, 2021, 138, 1234-1234.	0.6	7
90	A structured telephone-delivered intervention to reduce problem alcohol use (Ready2Change): study protocol for a parallel group randomised controlled trial. Trials, 2019, 20, 515.	0.7	6

#	Article	IF	CITATIONS
91	Combination of Nilotinib and Pegylated Interferon Alfa-2b Results in High Molecular Response Rates in Chronic Phase CML: Interim Results of the ALLG CML 11 Pinnacle Study. Blood, 2018, 132, 459-459.	0.6	6
92	Use of Machine Learning in 2074 Cases of Acute Myeloid Leukemia for Genetic Risk Profiling. Blood, 2019, 134, 1392-1392.	0.6	6
93	Pamidronate Therapy for One Year after Allogeneic Bone Marrow Transplantation (AlloBMT) Reduces Bone Loss from the Lumbar Spine, Femoral Neck and Total Hip Blood, 2004, 104, 2253-2253.	0.6	6
94	The therapeutic efficacy and prophylactic activity of doramectin against Dictyocaulus viviparus in cattle. Australian Veterinary Journal, 1995, 72, 349-351.	0.5	5
95	Protocol for a randomised controlled trial of cognitive bias modification training during inpatient withdrawal from alcohol use disorder. Trials, 2018, 19, 598.	0.7	5
96	Dissecting causes for improved survival among patients with acute myeloid leukemia in two different eras receiving identical regimens in sequential randomized studies. Blood Cancer Journal, 2018, 8, 84.	2.8	5
97	A phase II trial of continuous ixazomib, thalidomide and dexamethasone for relapsed and/or refractory multiple myeloma: the Australasian Myeloma Research Consortium (AMaRC) 16â€02 trial. British Journal of Haematology, 2021, 194, 580-586.	1.2	5
98	Combination of Nilotinib and Pegylated Interferon Alfa-2B Results in High Rates of MR4.5 at 24 Months - Primary Analysis of the ALLG CML 11 Pinnacle Study. Blood, 2019, 134, 2926-2926.	0.6	5
99	Anti-Leukemic Activity of Single Agent Venetoclax in Newly Diagnosed Acute Myeloid Leukemia: A Sub-Set Analysis of the Caveat Study. Blood, 2019, 134, 462-462.	0.6	5
100	Preliminary Minimal Residual Disease Analysis of the Australasian Leukaemia & Lymphoma Group (ALLG) ALL8 Study of Front-Line Blinatumomab with Chemotherapy in Adults with Ph Negative B-Cell Acute Lymphoblastic Leukaemia. Blood, 2019, 134, 1300-1300.	0.6	5
101	Adverse impact of high donor CD3+ cell dose on outcome following tandem auto-NMA allogeneic transplantation for high-risk myeloma. Bone Marrow Transplantation, 2017, 52, 839-845.	1.3	4
102	Phase II trial of singleâ€agent panobinostat consolidation improves responses after subâ€optimal transplant outcomes in multiple myeloma. British Journal of Haematology, 2021, 193, 160-170.	1.2	4
103	A Capacity Building Program to Improve the Self-Efficacy of Key Workers to Support the Well-Being of Parents of a Child With a Disability Accessing an Early Childhood Intervention Service: Protocol for a Stepped-Wedge Design Trial. JMIR Research Protocols, 2019, 8, e12531.	0.5	4
104	A Phase-Ib/II Clinical Evaluation of Ponatinib in Combination with Azacitidine in FLT3-ITD and CBL-Mutant Acute Myeloid Leukemia (PON-AZA study). Blood, 2021, 138, 2350-2350.	0.6	4
105	Flexible Low-Intensity Combination Chemotherapy for Elderly Patients with Acute Myeloid Leukaemia. Drugs and Aging, 2007, 24, 481-488.	1.3	3
106	Interplanner variability in carrying out three-dimensional conformal radiation therapy for non-small-cell lung cancer. Journal of Medical Imaging and Radiation Oncology, 2008, 52, 293-296.	0.9	3
107	Risk and response adapted therapy for early stage Hodgkin lymphoma: a prospective multicenter study of the Australasian Leukaemia and Lymphoma Group/Trans-Tasman Radiation Oncology Group. Leukemia and Lymphoma, 2011, 52, 786-795.	0.6	3
108	Su1655 A Prospective Comparison of Cold Snare Polypectomy Using Traditional or Dedicated Cold Snares for the Resection of Small Sessile Colorectal Polyps. Gastrointestinal Endoscopy, 2016, 83, AB381.	0.5	3

#	Article	IF	CITATIONS
109	Switch to nilotinib versus continued imatinib in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) with detectable BCR-ABL after 2 or more years on imatinib: ENESTcmr 12-month (mo) follow-up Journal of Clinical Oncology, 2012, 30, 6505-6505.	0.8	3
110	Flow Cytometric Evaluation of Traditional and Novel Surface Markers for the Diagnosis of Plasma Cell Dyscrasias. Indian Journal of Hematology and Blood Transfusion, 2019, 35, 673-682.	0.3	2
111	TOP2A expression predicts responsiveness to carfilzomib in myeloma and informs novel combinatorial strategies for enhanced proteasome inhibitor cell killing. Leukemia and Lymphoma, 2021, 62, 337-347.	0.6	2
112	Cereblon pathway biomarkers and immune profiles in patients with myeloma receiving post-ASCT lenalidomide maintenance (LEOPARD). Leukemia and Lymphoma, 2021, 62, 2981-2991.	0.6	2
113	Comparison of Steady-State Imatinib (IM) Trough Levels, Clinical Response, and Safety Between Caucasian and Asian Patients with Chronic Lyeloid Leukemia in Chronic Phase (CML-CP) Treated with 400mg and 800mg Daily Doses of IM in the Tyrosine Kinase Inhibitor Optimization and Selectivity (TOPS) Study., Blood, 2009, 114, 1127-1127.	0.6	2
114	A Longitudinal Evaluation of Euroflow and Combined Quantitative Immunoprecipitation (QIP) and Free Light Chain (FLC) Mass Spectometry (MS) in Functional High Risk Multiple Myeloma. Blood, 2019, 134, 3090-3090.	0.6	2
115	Machine Learning of Genomic Factors in 1,961 Patients with Acute Myeloid Leukemia Identifies Patients with Very Good or Very Poor Prognosis Who Do Not Benefit from Allogeneic Hematopoietic Cell Transplant in First Remission. Blood, 2021, 138, 225-225.	0.6	2
116	Sa1951 Intrapatient Variability in Adalimumab Drug Levels Within and Across Cycles in Crohn's disease. Gastroenterology, 2016, 150, S414.	0.6	1
117	Study design of endoscopic polypectomy on clopidogrel (EPOC): A randomised controlled trial. Contemporary Clinical Trials Communications, 2019, 16, 100479.	0.5	1
118	A Randomized Study of Bortezomib, Cyclophosphamide and Dexamethasone Induction (VCD) Versus VCD and Daratumumab Induction Followed By Daratumumab Maintenance (VCDD) for the Initial Treatment of Transplant-Ineligible Patients with Multiple Myeloma (AMaRC 03-16). Blood, 2020, 136, 4-5.	0.6	1
119	Roar: A Phase Ib Trial of Oral Azacitidine (CC-486) in Combination with Lenalidomide and Dexamethasone (Rd) for Patients with Relapsed and/or Refractory (R/R) Multiple Myeloma Who Have Failed a Prior Lenalidomide-Containing Regimen. Blood, 2016, 128, 2121-2121.	0.6	1
120	Association of early molecular response to nilotinib with probability of cytogenetic response in chronic myeloid leukemia patients (pts) who fail imatinib Journal of Clinical Oncology, 2010, 28, 6513-6513.	0.8	1
121	High Plasma Levels of TGF-α and IL-6 at Diagnosis Predict Early Molecular Response Failure and Transformation in CML. Blood, 2014, 124, 1788-1788.	0.6	1
122	P-055: Extracellular RNA: an emerging biomarker for therapeutic monitoring in multiple myeloma. Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, S68-S69.	0.2	1
123	Response Adaptive Salvage Treatment with Carfilzomib-Thalidomide-Dexamethasone for Newly Diagnosed Transplant Eligible Multiple Myeloma Patients Failing Front-Line Bortezomib-Based Induction Therapy - Final Analysis from the Australasian Leukemia and Lymphoma Group (ALLG) MM17 Trial, Blood, 2021, 138, 1663-1663.	0.6	1
124	An Australasian Leukemia Lymphoma Group (ALLG) Phase 2 Study to Investigate Novel Triplets to Extend Remission with Venetoclax in Elderly (INTERVENE) Acute Myeloid Leukemia. Blood, 2021, 138, 368-368.	0.6	1
125	A Randomized Study of Bortezomib, Cyclophosphamide and Dexamethasone Induction (VCD) Versus VCD and Daratumumab Induction Followed By Daratumumab Maintenance (VCDD) for the Initial Treatment of Transplant-Ineligible Patients with Multiple Myeloma (AMaRC 03-16). Blood, 2021, 138, 2728-2728.	0.6	1
126	Cold snare polypectomy of colorectal polyps â‰≇€Š10 mm on clopidogrel: Australian and New Zealand randomized controlled trial. Endoscopy International Open, 2022, 10, E745-E752.	0.9	1

JOHN REYNOLDS

#	Article	IF	CITATIONS
127	2525. International Journal of Radiation Oncology Biology Physics, 2006, 66, S502.	0.4	0
128	Sa1183 Adverse Events to Thiopurines Can Be Overcome and the Majority of Patients Respond to Therapy - Clinical Outcomes From the EATME Study. Gastroenterology, 2015, 148, S-250.	0.6	0
129	Tu1328 Final Thiopurine Metabolite Levels and Shunter Status Can Be Predicted After Six Weeks of Thiopurine Therapy - Biochemical Outcomes From the EATME Study. Gastroenterology, 2015, 148, S-861.	0.6	0
130	Intervention outcomes from a randomised controlled trial of diabetes prevention: Mothers after Gestational Diabetes in Australia Diabetes Prevention Program (MAGDA-DPP). Diabetes Research and Clinical Practice, 2016, 120, S59.	1.1	0
131	Augmentation with preâ€emptive macrogolâ€based osmotic laxative does not significantly improve standard bowel preparation in unselected patients: A randomized trial. JGH Open, 2019, 3, 374-380.	0.7	0
132	Planned withdrawal of dexamethasone after pomalidomide low dose dexamethasone induction for lenalidomide refractory multiple myeloma (ALLG MM14). Haematologica, 2021, , .	1.7	0
133	Two Year Data from a Prospective Safety Study Analyzing the Consequences of Imatinib Mesylate Inhibition of Sensitive Kinases Other Than bcr-abl in Patients with Previously Untreated Chronic Phase CML Blood, 2006, 108, 2147-2147.	0.6	0
134	Molecular Response to Imatinib Is Dependent on Dose in CML Patients with Low OCT-1 Influx Activity. Patients with High Activity May Respond Equally Well to Standard or Increased Dose Imatinib Blood, 2006, 108, 738-738.	0.6	0
135	Inclusion of RBC-Transfusion Dependency Can Improve the Prognostic Value of Revised-IPSS in MDS Patients. Blood, 2014, 124, 1923-1923.	0.6	Ο
136	Early Bortezomib Failure Predicts Shorter PFS: a Retrospective Analysis from 4 Victorian Centres. Blood, 2016, 128, 5708-5708.	0.6	0
137	TOP2A a New Predictive Marker of Response to Carfilzomib in Multiple Myeloma. Blood, 2016, 128, 4461-4461.	0.6	0
138	RBC-Transfusion Dependency Improves the Prognostic Value of the Revised-IPSS in MDS Patients: Analysis of South Australian and Dusseldorf MDS Registries. Blood, 2016, 128, 1998-1998.	0.6	0
139	Pomalidomide Alone or in Combination with Low Dose Dexamethasone As Maintenance Following Induction with Pomalidomide and Low Dose Dexamethasone in Relapsed and Refractory Myeloma (ALLG) Tj ETQ	q1 d.@. 78	43 b4 rgBT /C
140	Phase 2 Trial of the Combination of Ixazomib, Thalidomide and Dexamethasone (ITD) in Relapsed/Refractory Myeloma: Planned Preliminary Analysis. Blood, 2018, 132, 3265-3265.	0.6	0
141	Preliminary Analysis of the Australasian Leukaemia and Lymphoma Group (ALLG) MM17 Trial: Response Adaptive Salvage Treatment with Carfilzomib-Thalidomide-Dexamethasone (KTd) for Newly Diagnosed Transplant Eligible Multiple Myeloma Patients Failing Front-Line Bortezomib-Based Induction Therapy. Blood, 2018, 132, 3279-3279.	0.6	0
142	A Sequential Cohort Study Comparing Kappamab Alone to Kappamab, Lenalidomide and Low Dose Dexamethasone in Kappa-Restricted Relapsed Refractory Multiple Myeloma (AMaRC 01-16). Blood, 2019, 134, 3144-3144.	0.6	0
143	Identification of Novel Immune Cell Populations in Lenalidomide Refractory Relapsed Multiple Myeloma Patients Treated with Pomalidomide and Low Dose Dexamethasone. Blood, 2019, 134, 3186-3186.	0.6	0
144	Preliminary Analysis of the MM21 Trial: Response Adaptive Salvage Treatment with Daratumumab-Lenalidomide-Dexamethasone (DRd) for Newly Diagnosed Transplant Eligible Multiple Myeloma Patients Failing Front-Line Bortezomib-Based Induction Therapy. Blood, 2021, 138, 1665-1665.	0.6	0

#	Article	IF	CITATIONS
145	Immune Cell Profiles in Patients Treated with Lenalidomide and Alternate Day Prednisolone Maintenance Post Upfront ASCT for Multiple Myeloma (LEOPARD Trial). Blood, 2020, 136, 34-35.	0.6	0